Compare IDEXX Laboratories, Inc. (IDXX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vale SA — how do they compare? IDEXX Laboratories, Inc. trades at $521.77 (market cap $40.43B), while Vale SA trades at $13.44 (market cap $57.32B). The key difference: Vale SA is the larger of the two by market cap, and Vale SA pays a 8.87% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Vale SA for 109 Days on average.
| IDXX | VALE | |
|---|---|---|
Market Cap | $40.43B | $57.32B |
Volume | 692,164 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $766.68 | $17.82 |
52-Week Low | $504.70 | $10.75 |
Typical Hold Time | 46 Days | 109 Days |
Enterprise Value | $41.32B | $73.56B |
Dividend Yield | — | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
VALE trades at $13.61, down 3.34% amid broader market weakness in steel producers. The stock shows bearish technical signals with recent earnings misses in Q4 2025 and Q1-Q2 2026. Fundamentals reveal declining revenue from $43.8B in 2022 to $38.4B in 2025, with net income margin compressing to 5.11%. Analyst consensus remains mixed with 32% buy ratings but a $16.21 price target suggesting 19% upside potential.
VALE faces headwinds from iron ore price volatility and rising operational costs, though its base metals segment shows growth potential. The current valuation at P/E 26.84 appears stretched given earnings pressure. Key risks include Brazilian regulatory exposure and cyclical commodity dependence, while the dividend yield of approximately 2.9% provides some income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
